Julien Sirois

This study integrates iPSC-derived microglia into human midbrain organoids to enhance microglial maturation and inflammatory signaling, revealing altered transcriptional signatures in dopaminergic neurons and astrocytes.

This study identifies gut microbiota-derived extracellular vesicles as mediators linking intestinal dysbiosis to neuroimmune activation in Long COVID.

This study shows fibrinogen has opposing effects on human oligodendrocyte lineage cells depending on their maturation stage, inhibiting early differentiation but enhancing myelination in mature cells.

This study shows that TNF and IFNγ inhibit human OPC differentiation into oligodendrocytes and promote an astrocyte-like reactive phenotype, potentially contributing to impaired myelin repair in MS.

This study shows that midbrain organoids with SNCA gene triplication exhibit PD-like neural activity changes, which can be reversed by dopamine agonists.

The paper uses single-cell RNA sequencing to identify subpopulations of glial progenitors in iPSC-derived oligodendroglial lineage cultures and characterizes their differentiation response.

The paper develops a SOX10 reporter system to improve the differentiation of oligodendrocytes from iPSCs, enhancing reproducibility and maturity.

This paper describes a method to generate human phrenic-like motor neurons from iPSCs to model ALS-related respiratory neuron degeneration.

The paper develops a flow cytometry pipeline called CelltypeR to annotate and characterize cell types in brain organoids, identifying dopamine neuron subtypes and tracking cell type dynamics over time.

The paper generates PRKN and PINK1-KO and double KO human iPSC lines using CRISPR/Cas9 to model Parkinson's disease.

This study uses midbrain organoids from SNCA triplication patients to model synucleinopathy features, showing increased alpha-synuclein expression and aggregation linked to dopaminergic neuron loss.

This study develops microfabricated disks to scale up midbrain organoid generation, reducing labor and variability while maintaining viability for Parkinson's disease research.